Depression with diabetes carried a third higher mortality than diabetes alone

Design

systematic review and random-effects meta-analysis of observational studies

Population

26 studies from nine geographic regions comparing depression with diabetes against diabetes alone

Primary outcome

all-cause mortality, cause-specific mortality and diabetes complications

Effect

all-cause mortality RR 1.30 (95% CI 1.21-1.39); complications RR 1.28 (1.18-1.40); metabolic complications 1.63 (1.33-1.99)

A systematic review searched four databases from inception to December 2024 for studies comparing people who had both depressive disorder and diabetes against people with diabetes alone, and pooled 26 studies from nine geographic regions with random-effects models. The review deliberately excluded studies relying on self-reported questionnaires to identify depression, because those capture diabetes distress and subclinical symptoms as well as the disorder.

All-cause mortality was higher in the depression-diabetes group (relative risk 1.30, 95% CI 1.21-1.39), as was cardiovascular mortality (1.15, 1.02-1.29). Complications overall were more common (1.28, 1.18-1.40), driven by metabolic complications (1.63, 1.33-1.99) and cardiovascular complications (1.20, 1.11-1.29). Cerebrovascular complications (1.36, 0.99-1.87), nephropathy (1.09, 0.93-1.27) and peripheral vascular complications (0.97, 0.79-1.18) did not differ. Retinopathy was *less* common (0.84, 0.76-0.94), which most likely reflects who attends screening rather than who develops disease. The findings held across regions and across time, with heterogeneity that stratified analyses could not fully explain.

The pattern - metabolic and cardiovascular complications raised, microvascular ones not - points at glycaemic control and cardiovascular risk factor management rather than at a direct biological effect of depression. That is the actionable reading, and it is where the psychiatrist has leverage: the depression is being treated in our clinic, and the thing most likely to shorten this patient's life is a number we can ask for.

• Ask for the most recent HbA1c and blood pressure at psychiatric review in any patient with diabetes, and record them
• Treat a patient with depression and diabetes who has stopped attending diabetes follow-up as a high-risk case, not a non-adherent one
• Weigh the metabolic profile of the antidepressant where diabetes is present, and review weight and glucose after starting
• Flag the retinopathy finding for what it probably is - reduced screening attendance - and check when the last retinal examination was
• Where a joint clinic is not possible, send the HbA1c result and a specific request to the treating physician rather than a general letter

Why it matters

It puts the excess mortality of comorbid depression somewhere a psychiatrist can act on it - the glucose, not the mood.

Don't overread it

These are pooled observational studies with unexplained heterogeneity - they show worse outcomes alongside depression, not that treating the depression improves survival.

The statistics, in plain English

A relative risk of 1.30 for all-cause mortality means about 30% more deaths over the follow-up periods pooled, which on diabetes' already raised baseline is a substantial absolute number. The cardiovascular mortality interval (1.02-1.29) only just clears 1.0, so that specific estimate is fragile. The apparent protection against retinopathy (0.84, 0.76-0.94) is the clearest illustration of why an observational meta-analysis needs reading rather than quoting: depression does not protect the retina, and the likelier explanation is that people with depression attend fewer screening appointments, so less retinopathy is found.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.